Is Hims & Hers' $1.15 Billion Eucalyptus Acquisition a Game-Changer for Global Telehealth

Related Articles

Hims & Hers's GLP-1 Revenue Surge Erodes Core Profitability

2 weeks ago

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

6 months ago

Udine's High-Beta Bet: Navigating Volatility in Reddit and Hims & Hers

4 weeks ago

Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

1 months ago

Category

You may also like

Stock News•13 hours ago

Visa Just Put Hims & Hers in the Penalty Box—Here's Why It Matters

Visa's action against Hims & Hers could pressure telehealth subscription growth, as difficult cancellations push consumers to dispute charges with card providers. The move may raise churn and complian...

V

Share

Stock News•1 week ago

Hinge Health's Cylinder Deal Opens a $135B GI Care Growth Opportunity

Hinge Health's $105 million Cylinder acquisition opens a $135B GI care market, adding nearly 100 clients and about 2 million lives, expanding its musculoskeletal platform into a new specialty.

HNGE

Share

Stock News•1 week ago

HIMS Q2 Earnings Call Focuses on AI and Global Expansion

Hims & Hers raised its 2026 revenue outlook after AI boosted engagement and specialty care expanded, while Eucalyptus extended international reach despite margin pressure.

HIMS

Share

Stock News•2 weeks ago

Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States

Cuvo Health, a white-label telehealth platform, surpassed 300 exclusive providers serving all 50 states, per PRNewswire. The milestone expands its network capacity for entrepreneurs and established op...

Share